Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 6/20 | 0.46 |
| ▸ | LGALS9 | O00182 | 5/20 | 0.46 |
| ▸ | LGALS1 | P09382 | 5/20 | 0.46 |
| ▸ | LGALS7; LGALS7B | P47929 | 4/20 | 0.46 |
| ▸ | SELP | P16109 | 8/20 | 0.40 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.39 |
| ▸ | SELE | P16581 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9880217 | 0.91 | LGALS3 (0.38) | LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP | |
| SCHEMBL9880223 | 0.91 | LGALS3 (0.38) | LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP | |
| SCHEMBL9880216 | 0.89 | LGALS3 (0.54) | LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP | |
| SCHEMBL19726119 | 0.89 | LGALS3 (0.54) | LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP | |
| SCHEMBL9880213 | 0.89 | LMNA (0.43) | LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP | |
| SCHEMBL9880212 | 0.87 | LGALS3 (0.40) | LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP | |
| SCHEMBL17773524 | 0.86 | LGALS3 (0.53) | LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP | |
| SCHEMBL16768979 | 0.86 | USP2 (0.42) | LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP | |
| SCHEMBL18654211 | 0.85 | LGALS3 (0.46) | LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP | |
| SCHEMBL18650697 | 0.83 | LGALS3 (0.41) | LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883170-B2 | Adjuvant | WESTERN ILLINOIS UNIVERSITY RESEARCH FOUNDATION (US) | 2014-11-11 | — | — | US | disclosed |
| US-20120136142-A1 | Vaccine Compositions For Marburg Virus | SOUTHERN RESEARCH INSTITUTE (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136142-A1 | Vaccine Compositions For Marburg Virus | OSBPL3, OSBP2, CD81 | LGALS3 93/4885LGALS9 281/4885LGALS1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.